Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Interleukin 15 (IL15) Overview 6
Therapeutics Development 7
Interleukin 15 (IL15) - Products under Development by Stage of Development 7
Interleukin 15 (IL15) - Products under Development by Therapy Area 8
Interleukin 15 (IL15) - Products under Development by Indication 9
Interleukin 15 (IL15) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Interleukin 15 (IL15) - Products under Development by Companies 12
Interleukin 15 (IL15) - Products under Development by Universities/Institutes 14
Interleukin 15 (IL15) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Interleukin 15 (IL15) - Companies Involved in Therapeutics Development 23
Amgen Inc. 23
Calypso Biotech SA 24
Digna Biotech, S.L. 25
Interleukin 15 (IL15) - Drug Profiles 26
AM-0015 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
AMG-714 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
BNZ-1321 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
BNZ-1322 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
CALY-002 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
DB-039 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Monoclonal Antibody to Inhibit IL-2 and IL-15 for Oncology, Central Nervous System and Gastrointestinal Disorders - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Recombinant Protein to Activate IL-15 for Prostate Cancer and Metastatic Cancer - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Interleukin 15 (IL15) - Dormant Projects 35
Interleukin 15 (IL15) - Discontinued Products 36
Interleukin 15 (IL15) - Featured News & Press Releases 37
May 05, 2016: Celimmune Commences First-Ever Dosing with AMG 714 in Celiac Disease 37
Mar 31, 2016: Celimmune Commences Screening in Phase 2 Clinical Study in Refractory Celiac Disease Type II 37
Sep 23, 2015: Celimmune to Present Overview of Non-Dietary Celiac Disease Therapies in Development at Annual Celiac Support Association Meeting 38
Jun 22, 2015: Celimmune to Present Experimental Anti3IL315 Antibody AMG!714 at 16th International Celiac Disease Symposium 39
Jun 18, 2015: Admune Announces the First-in-Human Study of Heterodimeric IL-15 with Broad Applications for Cancer Immunotherapy 39
Dec 15, 2006: Genmab Announces AMG 714 Development Update 40
Mar 23, 2004: Amgen Announces Positive Humax-IL15 Interim Phase II Data 40
Jan 23, 2003: Genmab A/S Announces FDA Approval To Initiate Phase II Clinical Study Using HuMax-IL15 40
Sep 04, 2002: Genmab Announces Positive Results From Phase I/II Clinical Trial Of HuMax-IL15 For The Treatment Of Rheumatoid Arthritis 40
Jul 01, 2002: Genmab Announces The Human Antibody Therapeutic Drug HuMax-IL15 Effectively Treats Psoriasis 41
Oct 03, 2001: Genmab Initiates Phase I/II Clinical Trial With HuMax-IL15 For The Treatment Of Patients With Rheumatoid Arthritis 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44

List of Tables
Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Assessment by Monotherapy/Combination Products, H1 2016 16
Number of Products by Stage and Mechanism of Action, H1 2016 18
Number of Products by Stage and Route of Administration, H1 2016 20
Number of Products by Stage and Molecule Type, H1 2016 22
Pipeline by Amgen Inc., H1 2016 23
Pipeline by Calypso Biotech SA, H1 2016 24
Pipeline by Digna Biotech, S.L., H1 2016 25
Dormant Projects, H1 2016 35
Discontinued Products, H1 2016 36

List of Figures
Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Top 10 Indication, H1 2016 9
Comparative Analysis by Early Stage Products, H1 2016 11
Assessment by Monotherapy/Combination Products, H1 2016 16
Number of Products by Mechanism of Actions, H1 2016 17
Number of Products by Stage and Mechanism of Actions, H1 2016 17
Number of Products by Routes of Administration, H1 2016 19
Number of Products by Stage and Routes of Administration, H1 2016 19
Number of Products by Molecule Types, H1 2016 21
Number of Products by Stage and Molecule Type, H1 2016 21